CCKBR and medullary thyroid gland carcinoma: The CCK2R antagonist [177Lu]Lu-PP-F11N has recently shown clinical safety in patients with medullary thyroid cancer (MTC) 135, and further studies are under way including our own derivative [136; Figure 4].